Business News In Brief
William Demant snaps up Otix Global: Maker of Sonic hearing aids will be acquired by hearing aid maker William Demant for $50 million under a definitive merger deal announced Sept. 13. William Demant will pay $8.60 per share for the company, a 113% premium over the stock's Sept. 10 closing price of $4.04. Adding Otix, which changed its name from Sonic Innovations in 2009, will add a third brand to William Demant's Bernafon and Oticon hearing aid lines and bolster market share by 1%, according to William Demant. The latter firm controls 18% of the global hearing aid market, behind Sonova (23%) and Siemens (20%) but ahead of Starkey (12%), GN ReSound (11%) and Widex (9%), according to a June report from Jefferies International analyst Ingeborg Oie. Salt Lake City-based Otix reported 2009 sales of $95.8 million, down 23%; the decrease was due to "the slow economy" in North America and reimbursement changes in Germany in April 2009 that prohibited direct fitting fee payments from hearing aid retailers to doctors, the company explained. In conjunction with the merger, Otix announced it discontinued German operations as of Sept. 14. Danish firm William Demant, which generated 2009 revenue of $1 billion, up 6%, says that Otix' Sonic brand will now benefit from its "competitive infrastructure and R&D capabilities." The firm expects synergies to be achieved "within all areas, including development, production, logistics, marketing and distribution.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
Congress has launched an inquiry into 23andMe amid privacy concerns following its bankruptcy, particularly regarding the potential sale of sensitive user data. Additionally, a Cybernews report gave 40 DNA testing firms an average cybersecurity grade of D, citing widespread vulnerabilities and data breaches, along with inadequate public information about their security practices.
As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.
Will challenges in the way of designations of notified bodies that assess AI-enabled medical devices create delays and bottlenecks and slow EU medtech innovation?